Oral Ondansetron: An Effective Ambulatory Complement to Intravenous Ondansetron in the Control of Chemotherapy-Induced Nausea and Vomiting in Children
One hundred children with non-central nervous system malignancies received ondansetron at initiation of chemotherapy and every 8 hours for 5 days after cisplatin-containing therapy and for 3 days after other chemotherapy. Ondansetron was administered orally except with the intravenous chemotherapy....
Gespeichert in:
| Veröffentlicht in: | Pediatric hematology and oncology 1995, Vol.12 (1), p.67-72 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 72 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Pediatric hematology and oncology |
| container_volume | 12 |
| creator | Cohen, Ian J. Zehavi, Nurit Buchwald, Ilana Yaniv, Yitzchak Goshen, Yakov Kaplinsky, Chaim Zaizov, Rina |
| description | One hundred children with non-central nervous system malignancies received ondansetron at initiation of chemotherapy and every 8 hours for 5 days after cisplatin-containing therapy and for 3 days after other chemotherapy. Ondansetron was administered orally except with the intravenous chemotherapy. For the chemotherapy days, 72 of 93 children (76%) had complete or major control of vomiting on their worst day, 25% with cisplatin-containing protocols, 60% with ifosfamide-containing protocols, and 82% with other protocols. For the overall period, 71 of 93 children (76%) reported complete or major control of vomiting on the worst day, 14% with cisplatin, 60% with ifosfamide, and 83% with other chemotherapy. All had mild or no nausea. Of the 355 chemotherapy days, 228 children (64%) were emesisfree, 40% with cisplatin, 60% with ifosfamide, and 68% with other regimens. Of the overall period (541 days), 393 days were emesisfree, 45% with cisplatin, 71% with ifosfamide, and 86% with other regimes. Sixty-nine patients were not hospitalized, and oral ondansetron was given when chemotherapy was completed. Of the 241 ambulatory chemotherapy days, 178 (74%) were emesisfree. No significant toxicity was encountered. Oral ondansetron reduced hospitalization without reducing antiemetic efficiency in children. |
| doi_str_mv | 10.3109/08880019509029530 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_08880019509029530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_08880019509029530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-998bd8f1d97ba549799395985e404acd29594b72d81caac1152cb6022354e3953</originalsourceid><addsrcrecordid>eNp9kEGL1DAYhoMo6-zqD_Ag5OC1-qVJp416Gcq6DizORb2Wr0lqu6TJkKQr80f8vWaYcVGEPRXyPk9oHkJeMXjLGch30DQNAJMVSChlxeEJWbGqZAWs1_IpWR33IgPNc3IZ4x0AlLwuL8hFXQMHIVbk1y6gpTun0UWTgnfv6cbR62EwKk33hm7mfrGYfDjQ1s97a2bjEk2ebl0KeG-cX-LfOp0cTaPJcN69pX6g7Whmn88C7g_F1ulFGU2_4BINUnSafvfzlCb346i242R1MO4FeTagjebl-XtFvn26_tp-Lm53N9t2c1sowSEVUja9bgamZd1jJWQtJZeVbCojQKDSuYkUfV3qhilExXIb1a-hLHklTCb5FWGne1XwMQYzdPswzRgOHYPumLj7L3F2Xp-c_dLPRj8Y56Z5f3PeMSq0Q0CnpviAcSFEua4z9vGETW7wYcafPljdJTxYH_44_LG_-PCPPhq0aVQYTHfnl-BytUfe8BtM-qpC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Oral Ondansetron: An Effective Ambulatory Complement to Intravenous Ondansetron in the Control of Chemotherapy-Induced Nausea and Vomiting in Children</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Cohen, Ian J. ; Zehavi, Nurit ; Buchwald, Ilana ; Yaniv, Yitzchak ; Goshen, Yakov ; Kaplinsky, Chaim ; Zaizov, Rina</creator><creatorcontrib>Cohen, Ian J. ; Zehavi, Nurit ; Buchwald, Ilana ; Yaniv, Yitzchak ; Goshen, Yakov ; Kaplinsky, Chaim ; Zaizov, Rina</creatorcontrib><description>One hundred children with non-central nervous system malignancies received ondansetron at initiation of chemotherapy and every 8 hours for 5 days after cisplatin-containing therapy and for 3 days after other chemotherapy. Ondansetron was administered orally except with the intravenous chemotherapy. For the chemotherapy days, 72 of 93 children (76%) had complete or major control of vomiting on their worst day, 25% with cisplatin-containing protocols, 60% with ifosfamide-containing protocols, and 82% with other protocols. For the overall period, 71 of 93 children (76%) reported complete or major control of vomiting on the worst day, 14% with cisplatin, 60% with ifosfamide, and 83% with other chemotherapy. All had mild or no nausea. Of the 355 chemotherapy days, 228 children (64%) were emesisfree, 40% with cisplatin, 60% with ifosfamide, and 68% with other regimens. Of the overall period (541 days), 393 days were emesisfree, 45% with cisplatin, 71% with ifosfamide, and 86% with other regimes. Sixty-nine patients were not hospitalized, and oral ondansetron was given when chemotherapy was completed. Of the 241 ambulatory chemotherapy days, 178 (74%) were emesisfree. No significant toxicity was encountered. Oral ondansetron reduced hospitalization without reducing antiemetic efficiency in children.</description><identifier>ISSN: 0888-0018</identifier><identifier>EISSN: 1521-0669</identifier><identifier>DOI: 10.3109/08880019509029530</identifier><identifier>PMID: 7703044</identifier><identifier>CODEN: PHONEN</identifier><language>eng</language><publisher>Philadelphia, PA: Informa UK Ltd</publisher><subject>Administration, Oral ; Adolescent ; ambulatory care ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; chemotherapy ; Child ; Child, Preschool ; children ; Digestive system ; Female ; Humans ; Infant ; Infusions, Intravenous ; Male ; Medical sciences ; Nausea - prevention & control ; Neoplasms - drug therapy ; Ondansetron - administration & dosage ; Ondansetron - therapeutic use ; oral ondansetron ; Pharmacology. Drug treatments ; vomiting ; Vomiting - prevention & control</subject><ispartof>Pediatric hematology and oncology, 1995, Vol.12 (1), p.67-72</ispartof><rights>1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-998bd8f1d97ba549799395985e404acd29594b72d81caac1152cb6022354e3953</citedby><cites>FETCH-LOGICAL-c430t-998bd8f1d97ba549799395985e404acd29594b72d81caac1152cb6022354e3953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/08880019509029530$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/08880019509029530$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3444267$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7703044$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Ian J.</creatorcontrib><creatorcontrib>Zehavi, Nurit</creatorcontrib><creatorcontrib>Buchwald, Ilana</creatorcontrib><creatorcontrib>Yaniv, Yitzchak</creatorcontrib><creatorcontrib>Goshen, Yakov</creatorcontrib><creatorcontrib>Kaplinsky, Chaim</creatorcontrib><creatorcontrib>Zaizov, Rina</creatorcontrib><title>Oral Ondansetron: An Effective Ambulatory Complement to Intravenous Ondansetron in the Control of Chemotherapy-Induced Nausea and Vomiting in Children</title><title>Pediatric hematology and oncology</title><addtitle>Pediatr Hematol Oncol</addtitle><description>One hundred children with non-central nervous system malignancies received ondansetron at initiation of chemotherapy and every 8 hours for 5 days after cisplatin-containing therapy and for 3 days after other chemotherapy. Ondansetron was administered orally except with the intravenous chemotherapy. For the chemotherapy days, 72 of 93 children (76%) had complete or major control of vomiting on their worst day, 25% with cisplatin-containing protocols, 60% with ifosfamide-containing protocols, and 82% with other protocols. For the overall period, 71 of 93 children (76%) reported complete or major control of vomiting on the worst day, 14% with cisplatin, 60% with ifosfamide, and 83% with other chemotherapy. All had mild or no nausea. Of the 355 chemotherapy days, 228 children (64%) were emesisfree, 40% with cisplatin, 60% with ifosfamide, and 68% with other regimens. Of the overall period (541 days), 393 days were emesisfree, 45% with cisplatin, 71% with ifosfamide, and 86% with other regimes. Sixty-nine patients were not hospitalized, and oral ondansetron was given when chemotherapy was completed. Of the 241 ambulatory chemotherapy days, 178 (74%) were emesisfree. No significant toxicity was encountered. Oral ondansetron reduced hospitalization without reducing antiemetic efficiency in children.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>ambulatory care</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children</subject><subject>Digestive system</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nausea - prevention & control</subject><subject>Neoplasms - drug therapy</subject><subject>Ondansetron - administration & dosage</subject><subject>Ondansetron - therapeutic use</subject><subject>oral ondansetron</subject><subject>Pharmacology. Drug treatments</subject><subject>vomiting</subject><subject>Vomiting - prevention & control</subject><issn>0888-0018</issn><issn>1521-0669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEGL1DAYhoMo6-zqD_Ag5OC1-qVJp416Gcq6DizORb2Wr0lqu6TJkKQr80f8vWaYcVGEPRXyPk9oHkJeMXjLGch30DQNAJMVSChlxeEJWbGqZAWs1_IpWR33IgPNc3IZ4x0AlLwuL8hFXQMHIVbk1y6gpTun0UWTgnfv6cbR62EwKk33hm7mfrGYfDjQ1s97a2bjEk2ebl0KeG-cX-LfOp0cTaPJcN69pX6g7Whmn88C7g_F1ulFGU2_4BINUnSafvfzlCb346i242R1MO4FeTagjebl-XtFvn26_tp-Lm53N9t2c1sowSEVUja9bgamZd1jJWQtJZeVbCojQKDSuYkUfV3qhilExXIb1a-hLHklTCb5FWGne1XwMQYzdPswzRgOHYPumLj7L3F2Xp-c_dLPRj8Y56Z5f3PeMSq0Q0CnpviAcSFEua4z9vGETW7wYcafPljdJTxYH_44_LG_-PCPPhq0aVQYTHfnl-BytUfe8BtM-qpC</recordid><startdate>1995</startdate><enddate>1995</enddate><creator>Cohen, Ian J.</creator><creator>Zehavi, Nurit</creator><creator>Buchwald, Ilana</creator><creator>Yaniv, Yitzchak</creator><creator>Goshen, Yakov</creator><creator>Kaplinsky, Chaim</creator><creator>Zaizov, Rina</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1995</creationdate><title>Oral Ondansetron: An Effective Ambulatory Complement to Intravenous Ondansetron in the Control of Chemotherapy-Induced Nausea and Vomiting in Children</title><author>Cohen, Ian J. ; Zehavi, Nurit ; Buchwald, Ilana ; Yaniv, Yitzchak ; Goshen, Yakov ; Kaplinsky, Chaim ; Zaizov, Rina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-998bd8f1d97ba549799395985e404acd29594b72d81caac1152cb6022354e3953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>ambulatory care</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children</topic><topic>Digestive system</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nausea - prevention & control</topic><topic>Neoplasms - drug therapy</topic><topic>Ondansetron - administration & dosage</topic><topic>Ondansetron - therapeutic use</topic><topic>oral ondansetron</topic><topic>Pharmacology. Drug treatments</topic><topic>vomiting</topic><topic>Vomiting - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Ian J.</creatorcontrib><creatorcontrib>Zehavi, Nurit</creatorcontrib><creatorcontrib>Buchwald, Ilana</creatorcontrib><creatorcontrib>Yaniv, Yitzchak</creatorcontrib><creatorcontrib>Goshen, Yakov</creatorcontrib><creatorcontrib>Kaplinsky, Chaim</creatorcontrib><creatorcontrib>Zaizov, Rina</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Ian J.</au><au>Zehavi, Nurit</au><au>Buchwald, Ilana</au><au>Yaniv, Yitzchak</au><au>Goshen, Yakov</au><au>Kaplinsky, Chaim</au><au>Zaizov, Rina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Ondansetron: An Effective Ambulatory Complement to Intravenous Ondansetron in the Control of Chemotherapy-Induced Nausea and Vomiting in Children</atitle><jtitle>Pediatric hematology and oncology</jtitle><addtitle>Pediatr Hematol Oncol</addtitle><date>1995</date><risdate>1995</risdate><volume>12</volume><issue>1</issue><spage>67</spage><epage>72</epage><pages>67-72</pages><issn>0888-0018</issn><eissn>1521-0669</eissn><coden>PHONEN</coden><abstract>One hundred children with non-central nervous system malignancies received ondansetron at initiation of chemotherapy and every 8 hours for 5 days after cisplatin-containing therapy and for 3 days after other chemotherapy. Ondansetron was administered orally except with the intravenous chemotherapy. For the chemotherapy days, 72 of 93 children (76%) had complete or major control of vomiting on their worst day, 25% with cisplatin-containing protocols, 60% with ifosfamide-containing protocols, and 82% with other protocols. For the overall period, 71 of 93 children (76%) reported complete or major control of vomiting on the worst day, 14% with cisplatin, 60% with ifosfamide, and 83% with other chemotherapy. All had mild or no nausea. Of the 355 chemotherapy days, 228 children (64%) were emesisfree, 40% with cisplatin, 60% with ifosfamide, and 68% with other regimens. Of the overall period (541 days), 393 days were emesisfree, 45% with cisplatin, 71% with ifosfamide, and 86% with other regimes. Sixty-nine patients were not hospitalized, and oral ondansetron was given when chemotherapy was completed. Of the 241 ambulatory chemotherapy days, 178 (74%) were emesisfree. No significant toxicity was encountered. Oral ondansetron reduced hospitalization without reducing antiemetic efficiency in children.</abstract><cop>Philadelphia, PA</cop><pub>Informa UK Ltd</pub><pmid>7703044</pmid><doi>10.3109/08880019509029530</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0888-0018 |
| ispartof | Pediatric hematology and oncology, 1995, Vol.12 (1), p.67-72 |
| issn | 0888-0018 1521-0669 |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_08880019509029530 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Administration, Oral Adolescent ambulatory care Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences chemotherapy Child Child, Preschool children Digestive system Female Humans Infant Infusions, Intravenous Male Medical sciences Nausea - prevention & control Neoplasms - drug therapy Ondansetron - administration & dosage Ondansetron - therapeutic use oral ondansetron Pharmacology. Drug treatments vomiting Vomiting - prevention & control |
| title | Oral Ondansetron: An Effective Ambulatory Complement to Intravenous Ondansetron in the Control of Chemotherapy-Induced Nausea and Vomiting in Children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T04%3A04%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Ondansetron:%20An%20Effective%20Ambulatory%20Complement%20to%20Intravenous%20Ondansetron%20in%20the%20Control%20of%20Chemotherapy-Induced%20Nausea%20and%20Vomiting%20in%20Children&rft.jtitle=Pediatric%20hematology%20and%20oncology&rft.au=Cohen,%20Ian%20J.&rft.date=1995&rft.volume=12&rft.issue=1&rft.spage=67&rft.epage=72&rft.pages=67-72&rft.issn=0888-0018&rft.eissn=1521-0669&rft.coden=PHONEN&rft_id=info:doi/10.3109/08880019509029530&rft_dat=%3Cinformahealthcare_cross%3E10_3109_08880019509029530%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7703044&rfr_iscdi=true |